Skip to main content
OpenTrials

Clinical trial condition

Lymphoma

Explore clinical trials studying Lymphoma. Study availability and eligibility vary by location and protocol.

1,466 public trials 175 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma trial results

Completed

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

NCT03744676

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Local Institution - 0057 Los Angeles, California, United States
  • Local Institution - 0060 Denver, Colorado, United States
  • Local Institution - 0089 Miami, Florida, United States
  • Local Institution - 0081 Orlando, Florida, United States
View all 23 locations
View Trial Details
Completed

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

NCT03058289

Conditions
Bile Duct Cancer, Bile Duct Diseases, Bile Duct Neoplasms, +51 more
Locations
  • USC Norris Los Angeles, California, United States
  • USC HOAG Newport Beach, California, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States
  • UMASS Memorial Medical Center Worcester, Massachusetts, United States
View Trial Details
Completed

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

NCT03654716

Conditions
Brain Diseases, Brain Neoplasms, Brain Tumor, +16 more
Locations
  • UCSF Benioff Children's Hospital San Francisco, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States
  • Texas Children's Hospital, Baylor College of Medicine Houston, Texas, United States
View Trial Details
Completed

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

NCT01638533

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +125 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View Trial Details
Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

NCT01855750

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Tucson, Arizona, United States
  • Greenbrae, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
View all 201 locations
View Trial Details
Completed

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

NCT00670358

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Completed

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00243087

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +25 more
Locations
  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States
  • James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York, United States
  • M. D. Anderson Cancer Center at University of Texas Houston, Texas, United States
View Trial Details

Related conditions